Anavex Life Sciences (AVXL) News Today $9.11 +0.09 (+1.00%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Anavex Life Sciences (NASDAQ:AVXL) Trading Down 4.1% - Here's WhyAnavex Life Sciences (NASDAQ:AVXL) Shares Down 4.1% - Should You Sell?November 22 at 1:32 PM | marketbeat.comNwam LLC Buys Shares of 910,476 Anavex Life Sciences Corp. (NASDAQ:AVXL)Nwam LLC purchased a new position in Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 910,476 shares of the biotechnology company's stock, valued atNovember 22 at 9:43 AM | marketbeat.comGSA Capital Partners LLP Has $507,000 Stake in Anavex Life Sciences Corp. (NASDAQ:AVXL)GSA Capital Partners LLP trimmed its holdings in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 59.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 89,299 shares of the biotechnology company's sNovember 20 at 3:22 AM | marketbeat.comCritical Contrast: Palisade Bio (NASDAQ:PALI) and Anavex Life Sciences (NASDAQ:AVXL)November 17, 2024 | americanbankingnews.comAnavex Life Sciences (NASDAQ:AVXL) Hits New 52-Week High - Still a Buy?Anavex Life Sciences (NASDAQ:AVXL) Hits New 1-Year High - What's Next?November 11, 2024 | marketbeat.comAnavex Life Sciences (NASDAQ:AVXL) Stock, Insider Trading ActivityNovember 9, 2024 | benzinga.comAnavex Life Sciences (NASDAQ:AVXL) Shares Up 8.1% - Here's WhyAnavex Life Sciences (NASDAQ:AVXL) Trading Up 8.1% - Time to Buy?November 8, 2024 | marketbeat.comAnavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval ScenarioNovember 6, 2024 | seekingalpha.comAnavex: Understanding Their Latest Alzheimer's Data News With CautionNovember 5, 2024 | seekingalpha.comAnavex Life Sciences: Buy Rating Driven by Promising Blarcamesine Developments and Market ExpansionNovember 4, 2024 | markets.businessinsider.comAnavex Life Sciences' (AVXL) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $40.00 target price on shares of Anavex Life Sciences in a research report on Monday.November 4, 2024 | marketbeat.comAnavex Life Sciences (NASDAQ:AVXL) Stock, Option ChainNovember 1, 2024 | benzinga.comAnavex Life Sciences (NASDAQ:AVXL) Stock Quotes, Forecast and News SummaryNovember 1, 2024 | benzinga.comAnavex Life Sciences’ Promising Alzheimer’s Drug: Buy Rating Justified by Positive Clinical Outcomes and Strategic AdvantagesOctober 31, 2024 | markets.businessinsider.comAnavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024October 31, 2024 | markets.businessinsider.comAnavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024October 31, 2024 | globenewswire.comBuy Rating Affirmed for Anavex Life Sciences Amid Promising Clinical Developments and Market ProspectsOctober 19, 2024 | markets.businessinsider.comAnavex Life Sciences (NASDAQ:AVXL) Receives Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of Anavex Life Sciences in a research note on Friday.October 18, 2024 | marketbeat.comAnavex Reports Promising EEG Biomarker Results From Phase 2 Study Of ANAVEX 3-71 For SchizophreniaOctober 17, 2024 | markets.businessinsider.comAnavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of SchizophreniaOctober 17, 2024 | globenewswire.comAnavex Life Sciences Corp. (NASDAQ:AVXL) Sees Significant Decline in Short InterestAnavex Life Sciences Corp. (NASDAQ:AVXL - Get Free Report) was the recipient of a large drop in short interest in September. As of September 30th, there was short interest totalling 17,590,000 shares, a drop of 10.3% from the September 15th total of 19,610,000 shares. Based on an average daily volume of 903,000 shares, the short-interest ratio is currently 19.5 days.October 15, 2024 | marketbeat.comAnavex Life Sciences Corp (AVXL) Q3 2024 Earnings Call Highlights: Strong Cash Position and ...October 9, 2024 | finance.yahoo.comAnavex Life Sciences (NASDAQ:AVXL) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comRenaissance Technologies LLC Purchases 386,537 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL)Renaissance Technologies LLC raised its stake in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 483.8% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 466,437 shares of the biotechnology company's stock after purchasing an additionalOctober 3, 2024 | marketbeat.comAnavex Life Sciences Corp.September 15, 2024 | wsj.comAnavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024September 3, 2024 | globenewswire.comAnavex Life Sciences Corp. (NASDAQ:AVXL) Short Interest UpdateAnavex Life Sciences Corp. (NASDAQ:AVXL - Get Free Report) was the recipient of a large growth in short interest in July. As of July 31st, there was short interest totalling 19,880,000 shares, a growth of 7.8% from the July 15th total of 18,440,000 shares. Based on an average trading volume of 1,220,000 shares, the short-interest ratio is currently 16.3 days.August 17, 2024 | marketbeat.comAnavex Life Sciences (NASDAQ:AVXL) Shares Down 5.7% Anavex Life Sciences (NASDAQ:AVXL) Trading Down 5.7%August 16, 2024 | marketbeat.comAnavex Life Sciences (NASDAQ:AVXL) Trading Down 6.9%Anavex Life Sciences (NASDAQ:AVXL) Trading Down 6.9%August 7, 2024 | marketbeat.comAnavex Life Sciences (NASDAQ:AVXL) Announces Earnings ResultsAnavex Life Sciences (NASDAQ:AVXL - Get Free Report) announced its earnings results on Tuesday. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. During the same quarter in the previous year, the company posted ($0.14) earnings per share.August 7, 2024 | marketbeat.comBuy Rating on Anavex Life Sciences Amid Anticipated European Approval and Market Opportunity for Alzheimer’s Drug BlarcamesineAugust 7, 2024 | markets.businessinsider.comAnavex Life Sciences Corp.: Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business UpdateAugust 7, 2024 | finanznachrichten.deAnavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business UpdateAugust 7, 2024 | finance.yahoo.comBuy Rating on Anavex Life Sciences: Upcoming Catalysts and Positive Trial Outcomes Fuel OptimismAugust 7, 2024 | markets.businessinsider.comAnavex Life Sciences Corp. (AVXL) Q2 2024 Earnings Call TranscriptAugust 7, 2024 | seekingalpha.comAnavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business UpdateAugust 6, 2024 | globenewswire.comAnavex Life Sciences (AVXL) Scheduled to Post Earnings on TuesdayAnavex Life Sciences (NASDAQ:AVXL) will be releasing earnings before the market opens on Tuesday, August 6, Zacks reports.August 2, 2024 | marketbeat.comAnavex Life Sciences (NASDAQ:AVXL) Earns Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Anavex Life Sciences in a research note on Thursday.August 1, 2024 | marketbeat.comAnavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024August 1, 2024 | globenewswire.comBuy Rating Affirmed for Anavex Life Sciences on Blarcamesine’s Promising Alzheimer’s Treatment PotentialJuly 31, 2024 | markets.businessinsider.comAnavex: An Update To Their Phase 2b/3 Alzheimer's Trial DataJuly 30, 2024 | seekingalpha.comAnavex Life Sciences (NASDAQ:AVXL) Trading Down 4.3%Anavex Life Sciences (NASDAQ:AVXL) Stock Price Down 4.3%July 30, 2024 | marketbeat.comAnavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X ConferenceJuly 30, 2024 | globenewswire.comAnavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not SurprisingJuly 29, 2024 | seekingalpha.comAnavex Life Sciences Shares Rise on Positive Results of Alzheimer's Clinical TrialJuly 29, 2024 | marketwatch.comNeurodegenerative Disease-Focused Anavex Life Sciences' Alzheimer's Candidate Slows Disease Progression By Almost 39%July 29, 2024 | finance.yahoo.comAnavex Life Sciences (NASDAQ:AVXL) Shares Gap Up to $6.74Anavex Life Sciences (NASDAQ:AVXL) Shares Gap Up to $6.74July 29, 2024 | marketbeat.comResults from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association ConferenceJuly 28, 2024 | globenewswire.comEF Hutton Initiates Coverage of Anavex Life Sciences (AVXL) with Buy RecommendationJuly 23, 2024 | msn.comAnavex Life Sciences (NASDAQ:AVXL) Shares Up 8.5%Anavex Life Sciences (NASDAQ:AVXL) Trading 8.5% HigherJuly 23, 2024 | marketbeat.com Get Anavex Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter. Email Address Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out? (Ad)Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too? Click Here For Your Free Guide AVXL Media Mentions By Week AVXL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AVXL News Sentiment▼0.830.49▲Average Medical News Sentiment AVXL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AVXL Articles This Week▼44▲AVXL Articles Average Week Get Anavex Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MRUS News XENE News EWTX News VRNA News DYN News BHC News VERA News KYMR News MOR News VCEL News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AVXL) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anavex Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anavex Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
